Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Norwegian authorities have requested evidence submission from manufacturers for number of medical technologies and IVD tests in relation to assessment for funding

Norway established in 2013 a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method”.

In this framework, all innovations should undergo HTA before being funded. Selection of methods is performed by the Ordering Forum (Bestillerforum). If the method is of national concern, it undergoes Single Technology Appraisal at national level followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum). Decision Forum has regular meetings to review results of assessments to the make funding decisions.

Recently, administrators of the “New Method” program have initiated technology assessments of 10 technologies and now have requested manufacturers to make submission of clinical and economic evidence.  

The call for evidence submission concerns the following 10 technologies:

See full text of request here.

If you need support with understanding of Norwegian process or development of evidence submission dossier, please, contact us.

Subscribe to our biweekly newsletter not to miss important reimbursement information.